Business Context and Reporting Period
This Form 8-K is a current report filed by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc.) on November 12, 2024. The filing reports a corporate governance event: the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Graydon Bensler as an independent member of the Board of Directors, effective November 7, 2024. Mr. Bensler brings over seven years of experience in financial consulting, investment banking, and investor relations, and holds a Chartered Financial Analyst (CFA) designation.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. It confirms there are no undisclosed arrangements regarding the director's selection and no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the correct registrant name is Qualigen Therapeutics, Inc. (Ticker: QLGN), not Aixcrypto Holdings, Inc.
- Confirm the effective date of Graydon Bensler's board appointment (November 7, 2024).
- Review the attached Director Agreement (Exhibit 10.1) for specific compensation terms.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.